Customization: | Available |
---|---|
Transport Package: | Foil Bag |
Specification: | 99% |
Suppliers with verified business licenses
Audited by an independent third-party inspection agency
Item |
Specifications |
Results |
Appearance |
White or yellowish crystalline powder |
Conforms |
Assay |
>98.0% |
99.3% |
Molecular weight |
392.6 |
Conforms |
Melting point |
165-167ºC |
166ºC |
Ratio of rotation |
+11°-+13° |
+11° |
Acidity |
Less 0.5ml |
0.23ml |
Chloride |
Less 0.016% |
Conforms |
Barium salt |
conforms |
Conforms |
Loss on drying |
Less 2.0% |
1.0% |
Residue on ignition |
Less 0.2% |
0.14% |
Chenodiol suppresses hepatic synthesis of both cholesterol and cholic acid, gradually replacing the latter and its metabolite, deoxycholic acid in an expanded bile acid pool. These actions contribute to biliary cholesterol desaturation and gradual dissolution of radiolucent cholesterol gallstones in the presence of a gall-bladder visualized by oral cholecystography. Bile acids may also bind the the bile acid receptor (FXR) which regulates the synthesis and transport of bile acids.
Chenodeoxycholic acid is a naturally occurring bile acid that is used to treat patients with genetic deficiencies in the synthesis of bile acids. When given in high doses, cholic acid replacement therapy has been linked to minor elevations in serum aminotransferase levels, but it has not been linked to instances of clinically apparent acute liver injury with jaundice.
Chenodiol suppresses hepatic synthesis of both cholesterol and cholic acid, gradually replacing the latter and its metabolite, deoxycholic acid in an expanded bile acid pool.